(Reuters) - Canada's health department said on Sunday the 1.5 million doses of the Astrazeneca Plc COVID-19 vaccine imported from Emergent BioSolutions' Baltimore facility were safe and met quality specifications.
The U.S. Food and Drug Administration (FDA) had stopped AstraZeneca from using the facility earlier this month and halted production of Johnson & Johnson's vaccine at the plant as it began investigations into an error that led to millions of doses of J&J's vaccine being ruined last month.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
